Relative impact of earlier diagnosis and improved treatment on survival for colorectal cancer: A US database study among elderly patients

Cancer Epidemiology

Volumn 38, Issue 6, 2014, Pages 733-740

  Tong, Liyue ^a,b   Ahn, Chul ^b   Symanski, Elaine ^a   Lai, Dejian ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Colorectal cancer; Survival; Tumor stage and size migration

Indexed keywords

FLUOROURACIL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; DATA BASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OCCULT BLOOD TEST; OUTCOME VARIABLE; OVERALL SURVIVAL; PRACTICE GUIDELINE; SIGMOIDOSCOPY; TUMOR VOLUME; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; MORTALITY; SURVIVAL; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84912127484     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.10.004     Document Type: Article

References (56)

1. Saif M.W., Chu EBiology of colorectal cancerCancer J 2010, 16(3):196-201.
2. Lang K., Korn J.R., Lee D.W., Lines L.M., Earle C.C., Menzin JFactors associated with improved survival among older colorectal cancer patients in the US: a population-based analysisBMC Cancer 2009, 9:227.
3. Nishihara R., Wu K., Lochhead P., Morikawa T., Liao X., Qian Z.R., et alLong-term colorectal-cancer incidence and mortality after lower endoscopyN Engl J Med 2013, 369:1095-1105.
4. Littlejohn C., Hilton S., Macfarlane G.J., Phull PSystematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancerBr J Surg 2012, 99:1488-1500.
5. Levin B., Lieberman D.A., McFarland B., Smith R.A., Brooks D., Andrews K.S., et alScreening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of RadiologyCA Cancer J Clin 2008, 58:130-160.
6. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et alIrinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet 2000, 355:1041-1047.
7. Rothenberg M.LEfficacy of oxaliplatin in the treatment of colorectal cancerOncology (Williston Park)2000, 14((12) Suppl11):9-14.
8. Sanoff H.K., Carpenter W.R., Sturmer T., Goldberg R.M., Martin C.F., Fine J.P., et alEffect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 yearsJ Clin Oncol 2012, 30:2624-2634.
9. Sanoff H.K., Carpenter W.R., Martin C.F., Sargent D.J., Meyerhardt J.A., Sturmer T., et alComparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerJ Natl Cancer Inst 2012, 104:211-227.
10. Grothey A., Sargent D., Goldberg R.M., Schmoll H.JSurvival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentJ Clin Oncol 2004, 22:1209-1214.
11. Levin B., Bond J.HColorectal cancer screening: recommendations of the U.SPreventive Services Task ForceAmerican Gastroenterological AssociationGastroenterology 1996, 111:1381-1384.
12. Selby J.V., Friedman G.D., Quesenberry C.P., Weiss N.SA case-control study of screening sigmoidoscopy and mortality from colorectal cancerN Engl J Med 1992, 326:653-657.
13. Hewitson P., Glasziou P., Watson E., Towler B., Irwig LCochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an updateAm J Gastroenterol 2008, 103:1541-1549.
14. Phillips K.A., Liang S.Y., Ladabaum U., Haas J., Kerlikowske K., Lieberman D., et alTrends in colonoscopy for colorectal cancer screeningMed Care 2007, 45:160-167.
15. Lieberman D.AClinical practiceScreening for colorectal cancerN Engl J Med 2009, 361:1179-1187.
16. Medicare program; revisions to payment policies and five-year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002Final rule with comment periodFed Regist 2001, 66:55245-55503.
17. National Cancer InstituteCancer in Focus: Colorectal Cancer 2010, http://wwwcancergov/cancertopics/factsheet/cancer-advances-in-focus/colorectal.
18. Oncology ASoC (ASCO) Progress Against Colorectal Cancer http://wwwcancerprogressnet/downloads/timelines/progress_against_colorectal_cancer_timelinepdf.
19. Twelves C., Wong A., Nowacki M.P., Abt M., Burris H., Carrato A., et alCapecitabine as adjuvant treatment for stage III colon cancerN Engl J Med 2005, 352:2696-2704.
20. Lembersky B.C., Wieand H.S., Petrelli N.J., O'Connell M.J., Colangelo L.H., Smith R.E., et alOral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06J Clin Oncol 2006, 24:2059-2064.
21. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et alBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol 2008, 26:2013-2019.
22. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et alBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol 2007, 25:1539-1544.
23. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et alFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol 2009, 27:663-671.
24. Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Lonati V., Maspero F., et alFOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trialsClin Colorectal Cancer 2013, 12:145-151.
25. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.FOverview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly populationMed Care 2002, 40(8 Suppl.):IV-3-IV-18.
26. Howlader N., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., et alSEER Cancer Statistics Review, 1975-2010 2013, National Cancer Institute, Bethesda, MD, (posted to the SEER web site)http://seer.cancer.gov/csr/1975_2010/.
27. National Cancer Institute Number of Persons by Race and Hispanic Ethnicity for SEER Participants 2010, Accessed 01.03.10http://seer.cancer.gov/registries/datahtml.
28. Nattinger A.B., McAuliffe T.L., Schapira M.MGeneralizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care researchJ Clin Epidemiol 1997, 50(8):939-945.
29. Schrag D., Rifas-Shiman S., Saltz L., Bach P.B., Begg C.BAdjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancerJ Clin Oncol 2002, 20(19):3999-4005.
30. White A., Vernon S.W., Franzini L., Du X.LDisparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor or hospital characteristics?Cancer 2010, 116(19):4622-4631.
31. National Cancer Institute SEER Coding and Staging Manuals 2013, Accessed 12.06.13http://seer.cancer.gov/tools/codingmanuals/historicalhtml.
32. National Cancer Institute Modules STCoding CS Tumor Size 2012, Accessed 05.10.12http://training.seer.cancer.gov/collaborative/system/tnm/t/size/.
33. National Cancer Institute SEER extent of disease - 1988: Codes and coding instructions 1988.
34. National Cancer InstituteSEER*STAT Survival Analysis.
35. Deyo R.A., Cherkin D.C., Ciol M.AAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol 1992, 45:613-619.
36. National Cancer InstituteSEER-Medicare: Calculation of Comorbidity WeightsAccessed 01.11.13http://appliedresearch.cancer.gov/seermedicare/program/comorbidity.html.
37. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.RA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis 1987, 40:373-383.
38. National Cancer Institute8.1.2 SSSurveillance Research Program, SEER*Stat software () version 8.1.22013http://www.seer.cancer.gov/seerstat.
39. Cho H., Mariotto A.B., Cronin K.AEstimating relative survival for cancer patients from the SEER Program using expected rates based on Ederer I versus Ederer II method Surveillance Research Program, NCI, NCI, Technical Report #2011-01 2011.
40. Elkin E.B., Hudis C., Begg C.B., Schrag DThe effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999Cancer 2005, 104:1149-1157.
41. Tong L., Ahn C., Symanski E., Lai D., Du X.LEffects of newly developed chemotherapy regimens, comorbidities, chemotherapy-related toxicity on the changing patterns of the leading causes of death in elderly patients with colorectal cancerAnn Oncol 2014, 25:1234-1242.
42. Zauber A.G., Lansdorp-Vogelaar I., Knudsen A.B., Wilschut J., van Ballegooijen M., Kuntz K.MEvaluating test strategies for colorectal cancer screening: a decision analysis for the U.SPreventive Services Task ForceAnn Intern Med 2008, 149:659-669.
43. Gross C.P., Andersen M.S., Krumholz H.M., McAvay G.J., Proctor D., Tinetti M.ERelation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancerJAMA 2006, 296:2815-2822.
44. Smith R.A., Manassaram-Baptiste D., Brooks D., Cokkinides V., Doroshenk M., Saslow D., et alCancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screeningCA Cancer J Clin 2014, 64:30-51.
45. Phipps A.I., Scoggins J., Rossing M.A., Li C.I., Newcomb P.ATemporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007Am J Public Health 2012, 102:1791-1797.
46. Audisio R.A., Papamichael DTreatment of colorectal cancer in older patientsNat Rev Gastroenterol Hepatol 2012, 9:716-725.
47. Rutten H., den Dulk M., Lemmens V., Nieuwenhuijzen G., Krijnen P., Jansen-Landheer M., et alSurvival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgeryEur J Cancer 2007, 43:2295-2300.
48. van den Broek C.B., Dekker J.W., Bastiaannet E., Krijnen P., de Craen A.J., Tollenaar R.A., et alThe survival gap between middle-aged and elderly colon cancer patientsTime trends in treatment and survivalEur J Surg Oncol 2011, 37:904-912.
49. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et alImproved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialJ Clin Oncol 2009, 27:3109-3116.
50. Haller D.G., Tabernero J., Maroun J., de Braud F., Price T., Van Cutsem E., et alCapecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerJ Clin Oncol 2011, 29:1465-1471.
51. Jessup J.M., Stewart A., Greene F.L., Minsky B.DAdjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiationJAMA 2005, 294:2703-2711.
52. Papamichael D., Audisio R., Horiot J.C., Glimelius B., Sastre J., Mitry E., et alTreatment of the elderly colorectal cancer patient: SIOG expert recommendationsAnn Oncol 2009, 20:5-16.
53. Kohne C.H., Folprecht G., Goldberg R.M., Mitry E., Rougier PChemotherapy in elderly patients with colorectal cancerOncologist 2008, 13:390-402.
54. Lee L., Cheung W.Y., Atkinson E., Krzyzanowska M.KImpact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic reviewJ Clin Oncol 2011, 29:106-117.
55. Neugut A.I., Fleischauer A.T., Sundararajan V., Mitra N., Heitjan D.F., Jacobson J.S., et alUse of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based studyJ Clin Oncol 2002, 20:2643-2650.
56. Obuchowski N.A., Graham R.J., Baker M.E., Powell K.ATen criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancersAJR Am J Roentgenol 2001, 176:1357-1362.